Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-80948543 in Participants With NHL and CLL
NCT05424822Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Oct 2025
- Modality
- IgG Antibodies, Trispecific Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of JNJ-80948543 in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Dose-limiting Toxicity at 51 months, Number of Participants with Adverse Events at 51 months and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
JNJ-80948543
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05424822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05424822.